Collegium Pharmaceutical, Inc. COLL Convertible Debt (Non-Current)
Convertible Debt (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ConvertibleLongTermNotesPayable.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s convertible debt (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s convertible debt (non-current)?
- Collegium Pharmaceutical, Inc. (COLL) reported convertible debt (non-current) of $238.47M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s convertible debt (non-current) changed year-over-year?
- Collegium Pharmaceutical, Inc.'s convertible debt (non-current) increased by 0.4% year-over-year, from $237.43M to $238.47M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s convertible debt (non-current)?
- Over 5 years (2020 to 2025), Collegium Pharmaceutical, Inc.'s convertible debt (non-current) has grown at a 19.1% compound annual growth rate (CAGR), from $99.58M to $238.21M.
- What does convertible debt (non-current) mean?
- This represents the principal amount of debt instruments that can be converted into equity shares, with a maturity date extending beyond one year. It provides insight into the company's long-term financing strategy and potential future dilution for existing shareholders. This metric is critical for assessing the company's capital structure and the impact of potential equity conversion on earnings per share.